Read by QxMD icon Read


Andreas Kronbichler, Beth Blane, Mark A Holmes, Josef Wagner, Julian Parkhill, Sharon J Peacock, David R W Jayne, Ewan M Harrison
No abstract text is available yet for this article.
November 8, 2018: Rheumatology
Jocelyn H Leu, Omoniyi J Adedokun, Cynthia Gargano, Elizabeth C Hsia, Zhenhua Xu, Gopi Shankar
Objective: Golimumab immunogenicity was extensively studied during clinical development. As anti-drug antibody (ADA) detection with the standard bridging EIA (original-EIA) can yield false-negative results or underestimate ADA incidence and titres due to drug interference, a more sensitive assay was needed to determine clinical impact. Methods: A highly sensitive drug-tolerant EIA (DT-EIA) was developed and cross-validated against the original-EIA. Samples from phase-3 subcutaneous golimumab rheumatological trials (GO-FORWARD-rheumatoid arthritis, GO-REVEAL-psoriatic arthritis, GO-RAISE-ankylosing spondylitis) were then retested...
November 8, 2018: Rheumatology
Louise Warburton, Richard Collins, Chris Tomlinson
No abstract text is available yet for this article.
November 5, 2018: Rheumatology
Emmerik F A Leijten
No abstract text is available yet for this article.
November 5, 2018: Rheumatology
Matthew Palethorpe, Nathalie Latcham, Suresh Selvaraj, Marwan Bukhari
No abstract text is available yet for this article.
November 5, 2018: Rheumatology
Femke B G Lamers-Karnebeek, Johannes W G Jacobs, Timothy R D J Radstake, Piet L C M van Riel, Tim L Jansen
Objective: To establish whether serum adalimumab (ADA) trough level (ADA-TL) and antidrug antibody (ADA-ab) level predict flare after stopping ADA in established RA patients with long-standing low disease activity. Methods: From the clinical trial Potential Optimalisation and Effectiveness of TNF-blockers, 210 RA patients stopping ADA, who had been using ADA (40 mg/2 weeks) for >1 year with conventional synthetic DMARDs and who had low disease activity (DAS28 < 3...
October 31, 2018: Rheumatology
Deshire Alpizar-Rodriguez, Frauke Förger, Delphine Sophie Courvoisier, Cem Gabay, Axel Finckh
Objectives: To study the relationship between female reproductive and menopausal factors on functional and structural joint damage progression in women with RA. Methods: This is an observational cohort study of RA patients enrolled in the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. Information about female hormonal factors, such as pregnancies, menopause and hormonal therapy, were retrospectively retrieved using a specific questionnaire. The primary outcome was functional disability progression (HAQ) and the secondary outcome radiographic joint damage progression...
October 31, 2018: Rheumatology
Nicolas Iragorri, Glen Hazlewood, Braden Manns, Vishva Danthurebandara, Eldon Spackman
Objective: To systematically review the accuracy and characteristics of different questionnaire-based PsA screening tools. Methods: A systematic review of MEDLINE, Excerpta Medical Database, Cochrane Central Register of Controlled Trials and Web of Science was conducted to identify studies that evaluated the accuracy of self-administered PsA screening tools for patients with psoriasis. A bivariate meta-analysis was used to pool screening tool-specific accuracy estimates (sensitivity and specificity)...
October 31, 2018: Rheumatology
(no author information available yet)
No abstract text is available yet for this article.
October 30, 2018: Rheumatology
Giuseppe A Ramirez, Maria Efthymiou, David A Isenberg, Hannah Cohen
Cerebral and cardiovascular ischaemic events are frequent complications of SLE and constitute primary causes of permanent damage. However, the pathogenic determinants of an increased thromboembolic risk in patients with SLE are only partially understood. Atherosclerosis constitutes fertile soil for the development of thrombosis and shows disproportionately high prevalence and progression rates in patients with SLE. aPLs are independent risk factors for acute thrombosis but can also prompt long-term vascular inflammation...
October 30, 2018: Rheumatology
Amit Khatri, Ben Klünder, Paul M Peloso, Ahmed A Othman
Objectives: ABT-122 is a dual-variable-domain immunoglobulin that neutralizes both TNF-α and IL-17A. The objective of this work was to characterize exposure-response relationships for ABT-122 relative to adalimumab (TNF-α inhibitor) using ABT-122 phase 2 trials in patients with RA or PsA. Methods: Patients received subcutaneous doses of ABT-122 ranging from 60 mg every other week (EOW) to 240 mg every week, adalimumab 40 mg EOW, or placebo (PsA patients only) for 12 weeks...
October 29, 2018: Rheumatology
Julianne Elvenes, Silje Fismen, Gunn Marit Lynghaug, Gunnstein Bakland
No abstract text is available yet for this article.
October 29, 2018: Rheumatology
Thuy Nguyen Thi Phuong, Lan Nguyen Thi Ngoc, Hien Nguyen Xuan, Johan Rönnelid, Leonid Padyukov, Ingrid E Lundberg
No abstract text is available yet for this article.
October 26, 2018: Rheumatology
Lianne Kearsley-Fleet, Sunil Sampath, Liza J McCann, Eileen Baildam, Michael W Beresford, Rebecca Davies, Diederik De Cock, Helen E Foster, Taunton R Southwood, Wendy Thomson, Kimme L Hyrich
Objectives: Rituximab (RTX) may be a treatment option for children and young people with JIA, although it is not licensed for this indication. The aim of this study was to describe RTX use and outcomes among children with JIA. Methods: This analysis included all JIA patients within the UK Biologics for Children with Rheumatic Diseases study starting RTX. Disease activity was assessed at RTX start and at follow-up. The total number of courses each patient received was assessed...
October 24, 2018: Rheumatology
Yoshiyuki Abe, Taiki Ando, Masakazu Matsushita, Kurisu Tada, Ken Yamaji, Naoto Tamura
No abstract text is available yet for this article.
October 22, 2018: Rheumatology
Julie E Davis, Robert J Ward, James W MacKay, Bing Lu, Lori Lyn Price, Timothy E McAlindon, Charles B Eaton, Mary F Barbe, Grace H Lo, Matthew S Harkey, Jeffrey B Driban
Objectives: To determine whether greater effusion-synovitis volume and infrapatellar fat pad (IFP) signal intensity alteration differentiate incident accelerated knee OA (KOA) from a gradual onset of KOA or no KOA. Methods: We classified three sex-matched groups of participants in the Osteoarthritis Initiative who had a knee with no radiographic KOA at baseline (recruited 2004-06; Kellgren-Lawrence <2; n = 125/group): accelerated KOA: ⩾1 knee progressed to Kellgren-Lawrence grade ⩾3 within 48 months; common KOA: ⩾1 knee increased in radiographic scoring within 48 months; and no KOA: both knees had the same Kellgren-Lawrence grade at baseline and 48 months...
October 20, 2018: Rheumatology
Kristen Davies, Marwan Bukhari, Lesley Ottewell
No abstract text is available yet for this article.
October 12, 2018: Rheumatology
Riccardo Meliconi, Lia Pulsatelli
No abstract text is available yet for this article.
October 9, 2018: Rheumatology
Lisa Giovannini-Chami, Tiphanie P Vogel, Lisa R Forbes, Alexandre Fabre, Marie-Charlotte Trojani, Sylvie Leroy, Ophélie Antunes, Nathalie Vincent-Mefitiot, Sylvie Hiéronimus, Marie Baque-Juston, Christian Roux, Nathalie Tieulié
No abstract text is available yet for this article.
October 8, 2018: Rheumatology
Jessica L Turnier, Hermine I Brunner, Michael Bennett, Ashwaq Aleed, Gaurav Gulati, Wendy D Haffey, Sherry Thornton, Michael Wagner, Prasad Devarajan, David Witte, Kenneth D Greis, Bruce Aronow
Objectives: We used an unbiased proteomics approach to identify candidate urine biomarkers (CUBMs) predictive of LN chronicity and pursued their validation in a larger cohort. Methods: In this cross-sectional pilot study, we selected urine collected at kidney biopsy from 20 children with varying levels of LN damage (discovery cohort) and performed proteomic analysis using isobaric tags for relative and absolute quantification (iTRAQ). We identified differentially excreted proteins based on degree of LN chronicity and sought to distinguish markers exhibiting different relative expression patterns using hierarchically clustered log10-normalized relative abundance data with linked and distinct functions by biological network analyses...
October 4, 2018: Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"